Company Overview
GT Biopharma, Inc. (NASDAQ: GTBP) is a clinical stage immuno-oncology company focused on developing innovative therapies based on the Company's proprietary NK cell engager (TriKE®) technology. TriKE® therapeutic agents are targeted immunotherapeutic agents that simultaneously react with natural killer (NK) cells and cancer cells to selectively facilitate the killing of cancer cells.
Recent News
GT Biopharma to Present at the Centurion One Capital 9th Annual Toronto Growth Conference
Stock Overview
Symbol
GTBP
Exchange
Nasdaq
Market Cap
12.01m
Last Price
$0.4507
52-Week Range
$0.4011 - $3.85
02/25/2026 09:00 PM EST